about
Combating antimicrobial resistance: policy recommendations to save livesClinical Utility of Laboratory Detection of Clostridium difficile Strain BI/NAP1/027Burden of Nursing Home-Onset Clostridium difficile Infection in the United States: Estimates of Incidence and Patient Outcomes.Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance.Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.Treatment with monoclonal antibodies against Clostridium difficile toxins.Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands.Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches.Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 Update.Introduction to "A Compendium of Strategies To Prevent Healthcare-Associated Infections in Acute Care Hospitals: 2014 updates"Burden of Clostridium difficile infection in the United States.A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates.An epidemic, toxin gene-variant strain of Clostridium difficile.Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.A mouse model of Clostridium difficile-associated disease.Comparison of strain typing results for Clostridium difficile isolates from North America.Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in HospitalsNovel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies.Strategies to prevent catheter-associated urinary tract infections in acute care hospitals.Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostridium difficile.A simulation-based assessment of strategies to control Clostridium difficile transmission and infection.Fourteen-genome comparison identifies DNA markers for severe-disease-associated strains of Clostridium difficileCommunity-associated Clostridium difficile infection among veterans with spinal cord injury and disorder.Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.Differential immunodetection of toxin B from highly virulent Clostridium difficile BI/NAP-1/027.Analysis of Bacterial Communities during Clostridium difficile Infection in the MouseIn vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis.Breakthroughs in the treatment and prevention of Clostridium difficile infection.An Economic Analysis of Strategies to Control Clostridium Difficile Transmission and Infection Using an Agent-Based Simulation Model.The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databasesDevelopment and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in StoolRelapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects.Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.NAP1 strain type predicts outcomes from Clostridium difficile infection.Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027.Emergence and global spread of epidemic healthcare-associated Clostridium difficile.
P50
Q24632857-A37D304A-D1A0-4E8F-A51A-73F47B13D01BQ26778127-3657A2CA-2C1A-45D5-850D-97EDBF2183ACQ30196898-EEDBC5CC-7E8E-4B1F-B3D8-08318EDB2BCDQ33728296-84A3AB2A-4A85-4520-A79A-3367FAAA04FAQ33831557-2E23680C-C0CB-4771-B4FC-054332427881Q34093904-EA27768D-D1D0-4B11-8761-341AB55ECA30Q34105840-EB1DF68F-3FDB-4B85-A05F-1CBA6DE1437EQ34112832-5A43B2F3-88C6-4514-850C-34ED3FE96B85Q34190375-2F88AF97-4248-4E06-9612-DEE8BA29BA7AQ34419009-0B0F16B7-E7E0-445D-9D82-2CFDED36E7D4Q34440749-96686A3C-612F-427E-B078-2F404B77E1CEQ34464440-2B113170-C324-4966-9C1B-00D741B0BF96Q34470266-F06F0468-3818-41F2-A1CF-2B113ADC4A34Q34472146-38EF6BFA-479A-4A9E-AC75-6A54B8621A7CQ34591740-CF1DE6C4-70E5-446B-B870-4FAD595F42C2Q34598259-FF918480-0F63-4704-ABDA-90DB19EEA64DQ34627447-8437EC9F-E4A2-4585-985D-E466C4A83662Q34720061-E0439C92-B85F-40B9-85AF-DEB35A7D6B5AQ34801881-503DC487-93BF-491B-B001-DB2EF0CAA84AQ34847637-1145B84C-4A22-47F3-AF6F-2F41C06ABD66Q35050290-D0D1D903-3828-4A4E-9D84-876624E503F9Q35053644-8B3722C0-DE98-415B-9409-97FF6A529CEAQ35066741-E501B300-1421-4F30-AB07-F222BEE7A509Q35236676-25C459CB-D4DA-4AA9-B444-BC3B19B1AD29Q35364406-18A46475-9057-4E67-80DC-F5A63C3ECBCBQ35455312-9CC219A2-0850-47E4-A33B-F77A02622A0DQ35760741-038D1C0A-617C-4B49-A7AF-01FF751ACD3EQ35912682-4C5884CD-7731-4DF5-9EE6-C4BC841E7568Q35918139-96AEEC0B-E45D-4859-A5C9-60C39AE589A0Q35918566-69D08DD5-A10E-44F3-8D95-361DAF85198DQ35975135-9624DC14-00FC-4F21-BD58-6C32A909386BQ35996524-8F2B382A-51FC-4A38-A01D-BE04AEE6C8C2Q36066827-5D2F2EB8-BB4C-485B-AD5E-DEA543A41E50Q36071512-1D6F155F-23B8-47D0-95DD-FD44A3612FD9Q36075879-D14C7CCE-04F0-44FF-ABA0-9C0B2B18F411Q36276887-B1FFE3C9-A211-4334-880D-1ED4216DA318Q36379411-635A8509-9C01-41B2-A4F2-B03851A0A3CCQ36420815-58A43515-8038-4EF3-A7E8-05B48DDBF6C2Q36438993-5E27B80D-6347-45EC-AFDE-18630E0DDEB2Q36708973-5928CF46-A70E-4526-9B5F-B8A9D6D94216
P50
name
Dale N Gerding
@ast
Dale N Gerding
@en
Dale N Gerding
@nl
type
label
Dale N Gerding
@ast
Dale N Gerding
@en
Dale N Gerding
@nl
prefLabel
Dale N Gerding
@ast
Dale N Gerding
@en
Dale N Gerding
@nl